October 8, 2013
I made a personal submission to the EMA Consultation on the Publication and Access to Clinical-Trial Data, which you will find here.
As I said in the submission, public consultations are more effective when it is possible … to comment on submissions from others. My submission was partly in the form of a comment on the submission from EFPIA – which you can find here.
EFPIA continue to support the attack on the EMA transparency policy through the courts.Author : Jim Murray
BioTech, Consumers, English, Ethics in Business, EU Institutions, EU Priorities, Health, Health & Lifestyle, Innovation and Growth, Medicines, Pharmaceuticals, Public Affairs, Science & Research, Social Europe, Uncategorized